术前化疗对乳腺癌组织激素受体及耐药基因蛋白表达的影响

  目的  探讨术前化疗对乳腺癌组织激素受体及耐药基因蛋白表达的影响。   方法  收集2009年1月至2011年12月在江苏省肿瘤医院行术前化疗并手术治疗的92例乳腺癌患者临床资料，对化疗前B超引导下经皮粗针穿刺活检乳腺癌组织以及手术标本采用免疫组织化学SP法检测ER、PR、P-gp、GST-π、TOPO-Ⅱ的表达，比较化疗前后表达差异。   结果   经术前化疗后，ER、PR的阳性表达分别由65.2%、56.5%降为50.0%、52.2%，其中ER表达差异具有统计学意义（P < 0.05）。P-gp、GST-π的表达分别由54.3%、32.6%增高到82.6%、45.7%，前后比较差异具有统计学意义（P < 0.05），同时两者共表达的乳腺癌患者由化疗前的22例增加为32例，TOPO-Ⅱ的阳性表达则由化疗前的48.9%降为41.3%，前后差异无统计学意义（P>0.05）。   结论  术前化疗影响乳腺癌组织中激素受体及耐药基因蛋白的表达，监测其表达对于选择药物、判断预后以及指导治疗具有参考价值。 

Effects of Thalidomide on the Proliferation and Gap Junction Intercellular Communication of Prostate Cancer PC-3 Cells

  Objective   To explore the impact of preoperative chemotherapy on the expressions of hormone receptors and drug-resistant related proteins in breast cancer tissues.   Methods   Ninety-two breast cancer cases with preoperative chemotherapy were enrolled in Jiangsu Cancer Hospital between January 2009 and December 2011. The expressions of ER, PR, P-gp, GST-rt, and TOPO- II were detected and compared using the immunohistochemical streptavidin-peroxidase (S-P) method in breast cancer tissues harvested by ultrasound-guided core needle biopsy and operation.   Results   The positive expression rates of ER and PR were 65.2% and 56.5% before chemotherapy and 50.0% and 52.2% after chemotherapy, respectively. The former two had significant differences (P < 0.05). The positive expression rates of P-gp and GST-π, were 54.3% and 32.6% before chemotherapy and 82.6% and 45.7% after chemotherapy, respectively, showing significant differences (P < 0.05). The cases with the expression of both P-gp and GST-π increased from 22 to 32. The positive expression rate ofTOPO- II decreased from 48.9% to 41.3%, showing no significant difference (P>0.05), but with a decreasing trend.   Conclusion   Prechemotherapy affects the expression of hormone receptor and the drug-resistant related proteins. Monitoring their expression has a guiding significance for drug selection, prognostic judgment, and the following treatment regimen decision.